| drug name | Isavuconazole |
| classification | Triazole antifungal agent |
| pharmacokinetics | | absorption | Well absorbed after oral administration; however, bioavailability is variable and can be affected by food and other factors. Peak plasma concentrations are typically achieved within 2-4 hours. | | distribution | Distributes widely throughout the body, including the central nervous system. Concentrations in the cerebrospinal fluid can be high. | | metabolism | Primarily metabolized in the liver by CYP3A4 and possibly other pathways. | | elimination | Eliminated primarily via the liver, with a terminal half-life of approximately 15-24 hours. Renal elimination is minor. |
|
| suggested dosage | | adult male 25 years 70kg | | oral | Loading dose of 600 mg followed by 200 mg every 12 hours. Doses may vary based on the specific indication and patient factors; consult a healthcare professional for individualized dosing. |
| | notes | Individualized dosing is crucial and should be determined by a healthcare professional based on the patient's specific condition, renal function, liver function, and other relevant factors. |
|
| indications | | 1 | Treatment of invasive aspergillosis in patients who are not responding to or are intolerant of other antifungal agents. | | 2 | Treatment of candidemia in patients who are not responding to or are intolerant of other antifungal agents. | | 3 | Prophylaxis of invasive fungal infections in severely immunocompromised patients. |
|
| safety in pregnancy | Limited data available. Isavuconazole crosses the placenta. The potential risks to the developing fetus are not fully understood. Use only when clearly indicated and potential benefits outweigh potential risks. Consult with a specialist. |
| safety in breastfeeding | Isavuconazole is secreted into breast milk. The potential risks to the infant are not fully understood. Use with caution, and consider alternative treatment options if possible. Consult with a specialist. |
| side effects | | 1 | Gastrointestinal issues (nausea, vomiting, diarrhea) | | 2 | Liver dysfunction (elevated liver enzymes, hepatitis) | | 3 | Central nervous system effects (headache, dizziness, confusion) | | 4 | Hypotension | | 5 | Elevated blood levels of creatine kinase (muscle damage) | | 6 | Rash, pruritus |
|
| alternatives | |
| contraindications | | 1 | Severe hepatic impairment | | 2 | Known hypersensitivity to isavuconazole or related compounds |
|
| interactions | | 1 | Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase isavuconazole levels, potentially leading to toxicity. Strong CYP3A4 inducers (e.g., rifampicin) can decrease isavuconazole levels, potentially reducing efficacy. Consult with a pharmacist for a complete drug interaction list. |
|
| warnings and precautions | | 1 | Monitor liver function tests regularly during treatment. Adjust dosing in patients with renal or hepatic impairment. | | 2 | Monitor for signs and symptoms of myopathy (muscle pain, weakness). | | 3 | Caution in patients with pre-existing neurological disorders. | | 4 | Can cause visual disturbances; consult with an ophthalmologist if needed. |
|
| additional information | Isavuconazole is a newer antifungal agent. It is generally well-tolerated, but careful monitoring of potential side effects and drug interactions is important. Strict adherence to the prescribed regimen is crucial. |
| patient profile | |
